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Abstract
Aims/hypothesis The Coxsackie and adenovirus receptor (CAR) is a transmembrane cell-adhesion protein that serves as an entry
receptor for enteroviruses and may be essential for their ability to infect cells. Since enteroviral infection of beta cells has been
implicated as a factor that could contribute to the development of type 1 diabetes, it is often assumed that CAR is displayed on the
surface of human beta cells. However, CAR exists as multiple isoforms and it is not known whether all isoforms subserve similar
physiological functions. In the present study, we have determined the profile of CAR isoforms present in human beta cells and
monitored the subcellular localisation of the principal isoform within the cells.
Methods Formalin-fixed, paraffin-embedded pancreatic sections from non-diabetic individuals and those with type 1 diabetes
were studied. Immunohistochemistry, confocal immunofluorescence, electron microscopy and western blotting with isoform-
specific antisera were employed to examine the expression and cellular localisation of the five known CAR isoforms. Isoform-
specific qRT-PCR and RNA sequencing (RNAseq) were performed on RNA extracted from isolated human islets.
Results An isoform of CAR with a terminal SIV motif and a unique PDZ-binding domain was expressed at high levels in
human beta cells at the protein level. A second isoform, CAR-TVV, was also present. Both forms were readily detected
by qRT-PCR and RNAseq analysis in isolated human islets. Immunocytochemical studies indicated that CAR-SIV was
the principal isoform in islets and was localised mainly within the cytoplasm of beta cells, rather than at the plasma
membrane. Within the cells it displayed a punctate pattern of immunolabelling, consistent with its retention within a
specific membrane-bound compartment. Co-immunofluorescence analysis revealed significant co-localisation of CAR-
SIV with zinc transporter protein 8 (ZnT8), prohormone convertase 1/3 (PC1/3) and insulin, but not proinsulin. This
suggests that CAR-SIV may be resident mainly in the membranes of insulin secretory granules. Immunogold labelling
and electron microscopic analysis confirmed that CAR-SIV was localised to dense-core (insulin) secretory granules in
human islets, whereas no immunolabelling of the protein was detected on the secretory granules of adjacent exocrine
cells. Importantly, CAR-SIV was also found to co-localise with protein interacting with C-kinase 1 (PICK1), a protein
recently demonstrated to play a role in insulin granule maturation and trafficking.
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Unexpected subcellular distribution of a specific isoform
of the Coxsackie and adenovirus receptor, CAR-SIV, in human pancreatic
beta cells
Conclusions/interpretation The SIV isoform of CAR is abundant in human beta cells and is localised mainly to insulin secretory
granules, implying that it may be involved in granule trafficking and maturation. We propose that this subcellular localisation of
CAR-SIV contributes to the unique sensitivity of human beta cells to enteroviral infection.
Keywords Beta cells . Coxsackie and adenovirus receptor . Coxsackievirus B . Enterovirus . Insulin granule . Pancreas . Protein
interacting with C-kinase 1 (PICK1)
Abbreviations
CAR Coxsackie and adenovirus receptor
CAR-CT Coxsackie and adenovirus receptor C-terminus
CVB Coxsackievirus B
ECD Extracellular domain
FFPE Formalin-fixed, paraffin-embedded
LCM Laser capture microdissected
MCC Manders co-localisation coefficient
PC1/3 Prohormone convertase 1/3
PICK1 Protein interacting with C-kinase 1
RNAseq RNA sequencing
ZnT8 Zinc transporter protein 8
Introduction
Epidemiological and pathological studies have linked
enteroviral infections with the development of type 1
diabetes mellitus [1], but the mechanisms by which this
might promote islet autoimmunity remain uncertain. One
possibility is that islet cells are particularly sensitive to
infection by enteroviruses and, in accord with this, en-
terovirus serotypes that are most often associated with
type 1 diabetes (e.g. Coxsackievirus B [CVB]) have a
clear tropism for human beta cells [2–4]. Additional
support comes from evidence that enterovirus proteins
are present in the beta cells of individuals with type 1
diabetes [5, 6] and that specific viral response pathways
are activated in such cells [7, 8].
In order for enteroviruses to infect cells, they must bind to
specific cell surface proteins that serve as vehicles to mediate
their entry. Such binding is thought to alter the conformation
of the viral capsid to facilitate the entry of viral RNA into the
target cell. An endogenous cellular protein known as the
Coxsackie and adenovirus receptor (CAR) is one such viral
receptor. CAR is a transmembrane protein involved in
homotypic cell adhesion and tight junctional integrity [9] but
also serves as a primary cellular attachment protein for CVBs
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and adenoviruses [10], presumably in a subversion of its nor-
mal physiological role.
Full-length CAR is encoded by the CXADR gene, which
comprises eight exons and yields a protein with an extracel-
lular domain (ECD) linked by a single transmembrane region
to a cytoplasmic tail. Differential splicing yields at least five
different isoforms (Fig. 1a,b), but only two of these contain
the transmembrane domain and are likely to be retained within
cells. Structural studies have suggested that enteroviruses bind
to the D1 domain in the extracellular region of the protein [11,
12] and, accordingly, four of the isoforms (designated CAR-
SIV, CAR-TVV, CAR4/7 and CAR3/7) have been shown to
bind enterovirus. However, only CAR-SIV and CAR-TVV
retain the transmembrane domain and are thus able to mediate
a productive infection in cells. The two soluble isoforms are
released from cells and may protect from infection by seques-
tering active virus in the extracellular fluid [11].
Interestingly, the two isoforms bearing a transmembrane
domain vary only in the sequence of the final 26 (CAR-SIV)
or 13 (CAR-TVV) amino acids, but are differentially local-
ised within cells and may fulfil different functions [13]. The
CAR-SIV isoform (also known as CAREx7 [13]) is encoded
by the first seven exons of the human CXADR gene and is
expressed preferentially on the basolateral surface of
polarised cells. In contrast, the C-terminal region of the
CAR-TVV isoform (also known as CAREx8) is produced
from a cryptic splice site within the seventh exon linked to
exon 8, and is expressed apically [13]. The C-terminal re-
gion encodes a consensus PDZ-binding domain whose ami-
no acid sequence varies between the CAR-SIV and the
CAR-TVV forms, which probably accounts for the differ-
ential localisation of the two variants within polarised cells
[13–16]. In support of this, both the SIVand TVV forms of
CAR can interact with proteins such as membrane-
associated guanylate kinase, WW and PDZ domain-
containing protein 1b (MAGI-Ib), postsynaptic density pro-
tein 95 (PSD-95) [13, 15, 16] and zonula occludens-1 (ZO-
1) [14], but only the CAR-SIV isoform interacts with pro-
tein interacting with C-kinase 1 (PICK1) [13]. Strikingly,
PICK1 is abundantly expressed in beta cells and has recent-
ly been shown to control insulin granule trafficking. Indeed,
loss of PICK1 results in impaired glucose tolerance and
reduced serum insulin concentrations in experimental ani-
mals [17, 18]. Thus, an interaction between PICK1 and the
SIV isoform of CAR in beta cells could be of functional
importance.
To date, few studies have examined the expression and
distribution of CAR isoforms in human beta cells [3, 19].
Ylipaasto et al [3] confirmed a role for CAR by demonstrating
that pre-treatment of isolated human islets with a blocking
antibody (clone RmcB) protected the cells from CVB infec-
tion [3]. More recently, CAR expression was confirmed in
human pancreas, albeit using an antiserum that does not
discriminate between the various isoforms [20]. We have thus
characterised and mapped the expression and distribution of
CAR isoforms in human pancreas.
Methods
Tissue and cell lines Formalin-fixed, paraffin-embedded
(FFPE) pancreatic sections from the Exeter Archival
Diabetes Biobank (http://foulis.vub.ac.be/) and from the
Network for Pancreatic Organ donors with Diabetes
(nPOD; Gainesville, FL, USA) were studied. Samples
were from 21 non-diabetic individuals (age range 4–
47 years) and ten individuals with type 1 diabetes (age range
6–47 years; see electronic supplementary material [ESM]
Table 1). Isolated human islets were obtained from the
Oxford Centre for Islet Transplantation (Oxford, UK) or
purchased from Lonza (Basel, Switzerland). On arrival, is-
lets were cultured for 24 h at 37°C and then fixed and proc-
essed for immunostaining by standard immunofluorescence
(FFPE) techniques, or stored at −80°C for RNA extraction.
Ethics approval (West of Scotland Research Committee 4
[WoSREC4]; 15/WS/0258) was gained for all the samples
studied. The pancreatic tissue samples from the Exeter
Archival Diabetes Biobank and nPOD were selected based
on age of demise, and in the case of type 1 diabetes, duration
of disease; tissue quality; sample availability (which is re-
stricted within these biobanks) and appropriateness of tissue
for immunohistochemistry/immunofluorescence approaches.
Samples with extensive autolysis or evidence of other unrelated
pancreatic diseases were excluded. Blinding of donor type and
immunofluorescence stain was performed for the co-localisation
studies. The human beta cell lines EndoC-βH1 and 1.1B4 were
cultured as described in ESM Methods.
Antibodies Three different anti-CAR sera were employed
(ESM Table 2) based on their selective immunoreactivity
against the C-terminus (CAR-CT) or regions within the
ECD (CAR-ECD and CAR-RmcB) of the protein, respective-
ly, and validated as described below and in ESM Fig. 1. These
allowed the various isoforms of CAR to be distinguished, as
illustrated in Fig. 1b. All other antisera are described in ESM
Table 2.
Mutagenesis Site-directed mutagenesis was performed to re-
move the final three amino acids (SIV) of CAR-SIV to exam-
ine the specificity of the CAR-CT antiserum (ESMMethods).
Western blotting The production of CAR in human islets and
EndoC-βH1 cells and the specificity of the CAR-CT and
CAR-RmcB antisera were assessed using western blotting
(ESM Methods).
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Flow cytometry The specificity of the CAR-CT and CAR-
RmcB antisera was assessed using flow cytometry (ESM
Methods).
Immunohistochemistry This was performed using a standard
immunoperoxidase approach [21]. Bright-field image acqui-
sition was performed using a Nikon 50i Microscope fitted
with a DS-Fi camera and a DSL2 camera control unit
(Nikon, Kingston Upon Thames, UK). Antibody details and
conditions are described in ESM Table 2.
Immunofluorescence To examine multiple antigens within the
same section, FFPE samples were probed in a sequential man-
ner with up to three different antibodies (ESM Table 2) [22].
Pancreas sections were initially subjected to heat-induced epi-
tope retrieval in 10 mmol/l citrate buffer (pH 6), and relevant
antigen–antibody complexes were detected using secondary
antibodies conjugated with fluorescent dyes (Alexa Fluor anti-
mouse 488, anti-rabbit 555, and anti-guinea pig 568 or 647;
Invitrogen, Paisley, UK). Cell nuclei were stained with DAPI.
After mounting, images were captured either with a Leica
AF6000 microscope (Leica, Milton Keynes, UK), then were
processed using the standard LAS X Leica software platform
(Version 3.3.0.16799), or with a Leica SP8 confocal micro-
scope and Hyvolution2 deconvolution software (Scientific
Volume Imaging, Hilversum, the Netherlands). Co-
localisation analysis was undertaken with a JACoP plugin
from Image J, version 1.48 Java 1.6.0 _20 (https://imagej.
nih.gov/ij/plugins/track/jacop2.html).
Quantitative RT-PCR/semi-quantitative RT-PCR The relative
expression levels of the CAR-SIV, CAR-TVV, CAR4/7,
CAR3/7 and CAR2/7 isoforms in isolated human islets and
laser capture microdissected (LCM) islets were determined
using quantitative (q)RT-PCR (ESM Methods).
RNAseq RNA sequencing (RNAseq) was performed using
islets obtained from normoglycaemic human islet donors or
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Fig. 1 A description of the CAR isoforms and the selective expression of
CAR-SIV in human islets. (a) CAR protein structure. The signal peptide
(red) is cleaved to yield a mature protein with an ECD comprising two
immunoglobulin (Ig)-like domains, type 1 (blue) and type 2 (green). The
transmembrane domain (yellow) bridges the extracellular and cytoplas-
mic regions (pink), which terminates with a PDZ-binding domain (red).
(b) CXADR exon maps of the five differentially spliced isoforms. The
type 1 Ig domain is encoded by exons 2 and 3, while type 2 Ig-like
domain is encoded by exons 4 and 5. Isoforms 1 and 2 contain a trans-
membrane domain and are named CAR-SIV (or hCAR1, CAREx7) and
CAR-TVV (or hCAR2, CAREx8), respectively (denoted by the three ter-
minal amino acids on their C-termini). The soluble isoforms 3, 4 and 5 are
named CAR4/7, CAR3/7 and CAR2/7, respectively, reflecting exon in-
clusion or exclusion and lack of the transmembrane domain. The binding
regions of the different CAR antibodies are also shown. The CAR-CT
antiserum recognises amino acids 335–365 located at the C-terminus of
the CAR-SIV isoform but does not recognise the other CAR isoforms.
Both the CAR-ECD and CAR-RmcB antisera recognise epitopes within
the ECD, and are predicted to recognise the majority of the longer CAR
isoforms (CAR-SIV, CAR-TVV, CAR4/7 and potentially CAR3/7). (c, d)
Representative immunocytochemical analysis of the expression of differ-
ent CAR isoforms in normal control pancreas tissue stained with (c)
CAR-CT and (d) CAR-ECD antisera. Scale bars, 20 μm. The insets
below represent higher magnification images (of the areas outlined by
the black boxes) demonstrating the differential staining profile of the
CAR-CT antisera in the endocrine (+++) and exocrine pancreas (−), and
the CAR-ECD antisera in the endocrine (+++) and exocrine pancreas (+);
+++, strong; +, weak; −, negative. These results are representative of
findings in pancreas from eight non-diabetic individuals; aa, amino acids,
Ab., antibody
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EndoC-βH1 cells as previously described [23]. Genes and
transcripts were assigned a relative coverage rate as measured
in reads per kilobase of exon model per million mapped reads
and compared with 15 other normal human tissues, analysed
by RNAseq and deposited at the Illumina BodyMap 2.0
dataset (GEO accession number GSE30611), accessed on 9
August 2017.
Cryo-immune electron microscopy We used cryoimmune
electron microscopy to assess and quantify the localisation
of CAR-SIV, zinc transporter protein 8 (ZnT8), insulin and
proinsulin in human pancreas samples as described previously
[24] and in the ESM Methods.
Co-immunoprecipitation of PICK1 with CAR This was per-
formed in EndoC-βH1 cells and human islets as described
in ESM Methods.
Statistical analysis Immunofluorescence images of islets were
selected randomly from stained pancreas sections. The
Pearson correlation coefficient was used to estimate the co-
localisation between proteins using the JACoP plugin from
Image J. Values for the Pearson correlation coefficient ranged
from 0 for no correlation, to 1 for a positive correlation.
GraphPad Prism 5.04 (La Jolla, CA, USA) was employed
for all statistical analysis, and data are expressed as means
±SEM. Statistical significance was calculated using one-way
ANOVA, and the Bonferroni multiple comparison test was
used for multiple comparisons. A p value <0.05 was consid-
ered statistically significant.
Results
Differential CAR immunostaining in human pancreas The
availability of antisera directed against different regions of
the CAR protein (Fig. 1b) enabled the expression profiles of
the two isoforms bearing a transmembrane domain to be
studied. The antiserum designated CAR-CT was raised
against a peptide containing the C-terminal 35 amino acids
of the CAR-SIV protein and required the presence of the
triplet “SIV’ sequence at the immediate C-terminus for im-
munoreactivity. As such, it did not label any other isoform
of CAR. This specificity was confirmed by transfection of
1.1B4 cells with constructs encoding either the full-length
CAR-SIV or a variant in which the final three amino acids
(SIV) had been removed by targeted mutagenesis (ESM
Methods). Western blotting and immunofluorescence stain-
ing confirmed immunorecognition of the full-length CAR-
SIV isoform, but not the truncated form, by the CAR-CT
antiserum (ESM Fig. 1).
Two further CAR antibodies, CAR-ECD (Abcam,
Cambridge, UK) and RmcB (Merck Millipore, Watford,
UK), both of which recognise the ECD of human CAR, were
also used. By deploying a panel of approaches (western blot-
ting, immunofluorescence staining of fixed cells, flow cytom-
etry and immunohistochemistry in FFPE sections), it was
found that the CAR-ECD antiserum worked effectively in
both western blotting and immunohistochemistry, whereas
the RmcB clone was most suitable for immunofluorescence
staining of fixed cells or flow cytometry. As noted above, both
the CAR-ECD and RmcB antibodies recognise multiple iso-
forms of CAR including CAR-SIV, CAR-TVV and CAR4/7
(ESM Fig. 1b,c).
Use of these differentially specific antisera revealed that
various isoforms of CAR are expressed among the exocrine
and endocrine compartments of the human pancreas
(Fig. 1c,d). Importantly, the CAR-CT antiserum labelled only
islet cells (Fig. 1c) whereas use of the CAR-ECD anti-
serum resulted in labelling of both exocrine and endocrine
tissue (Fig. 1d). An identical staining pattern was confirmed
in a total of eight pancreases from non-diabetic donors (with-
in the Exeter and nPOD Biobanks), ranging in age from
4 weeks to 59 years (ESM Table 1).
Confirmation of SIV isoform expression by qRT-PCR in human
islets Isoform-specific primers were used to analyse CXADR
isoform expression (ESM Table 3) by qRT-PCR in RNA ex-
tracted from isolated human islets (ESM Table 4). This re-
vealed that transcripts encoding the CAR-SIV and CAR-
TVV isoforms were expressed at the highest levels, while
the soluble CAR4/7 isoform was less abundant (Fig. 2a).
The two shorter isoforms CAR3/7 and CAR2/7 were barely
detectable. These results were confirmed in a second set of
independent samples in which RNAwas isolated from LCM
islets (Fig. 2b; ESM Table 5). This was further confirmed by
RNAseq analysis of isolated human islets (Fig. 2c).
Importantly, CAR-SIV was enriched threefold compared with
CAR-TVV in the human pancreatic beta cell line EndoC-βH1
(ESM Fig. 2a; ESMMethods) [25], and semi-quantitative RT-
PCR analysis of RNA extracted from two highly purified
preparations of human islets revealed that the expression of
CAR-SIV was greater than that of CAR-TVV (ESM Fig. 2b).
Finally, the presence of the SIV isoform was verified by west-
ern blotting in isolated human islets and EndoC-βH1 cell
using the CAR-CT and CAR-ECD antisera (Fig. 2d).
The SIV isoform is expressed preferentially in human beta
cells To determine whether the SIV isoform of CAR is prefer-
entially localised to a specific endocrine cell subset, combined
immunofluorescence staining using anti-CAR-CT, insulin and
glucagon was performed. This revealed that expression of the
CAR-SIV isoform was restricted solely to beta cells in human
pancreas sections (Fig. 3a) and isolated human islets (Fig. 3b).
Somewhat surprisingly, rather than being localised to the cell
surface, the CAR-SIV isoform was distributed mainly within
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Fig. 3 The SIV isoform of CAR is expressed in pancreatic beta cells. (a)
Representative immunofluorescence staining of the CAR-SIV isoform
(CAR-CT antibody; green), insulin (light blue), glucagon (red) and
DAPI (dark blue) in an islet from a non-diabetic human pancreas. Scale
bars, 10μm. (b) CAR-SIV isoform staining in FFPE isolated human islets:
CAR-SIV (CAR-CT; green) and insulin (red) and DAPI (dark blue). The
enlarged region (from the area outlined by the dashed white box) demon-
strates co-localisation of CAR-CT and insulin staining (yellow). Scale
bars, 10 μm. (c) Granular distribution of CAR-SIV (green) and co-
localisation with insulin (red) and DAPI (dark blue) in the islet of a non-
diabetic pancreas. Scale bars, 5 μm. These results are representative of
findings in the pancreases of 15 non-diabetic individuals (ESM Table 1)
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Fig. 2 Confirmation of CAR-SIV isoform expression in human islets.
qRT-PCR analysis of CXADR isoform expression in (a) isolated human
islets (n = 5 individuals) and (b) LCM human islets (n = 2 individuals)
demonstrates that the SIV and TVV isoforms are highly expressed,
CAR4/7 is present at low levels, and CAR3/7 and CAR2/7 are barely
detectable. Data were normalised to the relative expression of three
housekeeping genes, β-actin, GAPDH and B2M. Relative expression is
presented as the mean ± SEM. (c) RNAseq data showing CAR isoform
expression in islets from five normoglycaemic individuals (mean ± SEM)
[23]. RPKM, reads per kilobase of exon model per million mapped reads.
(d) Confirmation of CAR-SIV protein expression in isolated human islets
and EndoC-βH1 cells as assessed by western blotting using CAR-CTand
CAR-ECD antisera and loading control glyceraldehyde 3-phosphate de-
hydrogenase (GAPDH). H., human
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the cytoplasm of beta cells. Confocal microscopy revealed
that CAR-SIV displayed a punctate distribution and that it
specifically co-localised with insulin, suggesting a possible
association with secretory granules (Fig. 3c). A similar pattern
of punctate immuno-co-localisation with insulin was observed
when using an alternative CAR antiserum (CAR-ECD; data
not shown).
To explore these relationships further, the expression of
CAR-SIV was investigated in the pancreases of a series of
people with type 1 diabetes (ten individuals; 3–42 years of
age; ESM Table 1, ESM Fig. 3) and islet autoantibody-
positive non-diabetic individuals (two participants, aged 18
and 37 years, respectively). The samples from individuals
with type 1 diabetes contained both insulin-deficient islets
and insulin-containing islets. CAR-SIVexpression was absent
from the insulin-deficient islets, but was clearly visible in re-
sidual insulin-containing islets. Neither the subcellular distri-
bution nor the staining intensity differed between the type 1
diabetic, autoantibody-positive non-diabetic and non-diabetic
islets (ESM Fig. 3 and data not shown). Finally, by applying
the CAR-CTantibody to a human tissue microarray (gift from
Alan Foulis; University of Glasgow, UK), it was confirmed
that the SIV isoform could be variously found at the surface
membrane (testes and bladder small cell carcinoma) and/or in
cytoplasmic regions (stomach and islets) within normal and
cancerous tissues (ESM Fig. 4). RNAseq data supported this
expression profile (ESM Fig. 4).
CAR-SIV co-localises with secretory granule proteins in beta
cells In order to verify the localisation of CAR-SIV in beta
cells, confocal co-immunofluorescence studies were per-
formed to localise certain other proteins (ZnT8, Fig. 4a;
prohormone convertase 1/3 [PC1/3], Fig. 4b; and proinsulin,
Fig. 4c) known to be present in secretory granules. Calculation
of the Pearson correlation coefficient confirmed that insulin
strongly associated with ZnT8 (0.94 ± 0.01; Fig. 4d).
Importantly, CAR-SIV also correlated strongly with insulin
(0.95 ± 0.02; Fig. 4d) and PC1/3 (0.81 ± 0.02; Fig. 4d). In
contrast, CAR-SIV did not associate with glucagon (0.05 ±
0.02; Fig. 4d,e) and was more weakly associated with proin-
sulin (0.55 ± 0.04; Fig. 4d). High-resolution confocal micros-
copy confirmed the co-localisation of CAR-SIV with ZnT8
(Fig. 4f) and PC1/3 (Fig. 4g), and showed that CAR-SIVand
proinsulin were less frequently co-localised (Fig. 4h). Using a
more sophisticated reciprocal analysis, it was confirmed that
the majority of CAR-SIV co-localised with insulin (Manders
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Fig. 4 CAR-SIV co-localisation with multiple insulin granule proteins
within the beta cell. Representative immunofluorescence staining of the
CAR-SIV isoform (CAR-CT antibody; green) and insulin (blue) in rela-
tion to insulin secretory granule proteins (red): (a) ZnT8, (b) PC1/3 and
(c) proinsulin. (d) Pearson correlation coefficient demonstrating the asso-
ciation between CAR-SIV and glucagon, insulin, ZnT8, PC1/3 and pro-
insulin, and between ZnT8 and insulin. Each data point represents a single
islet, and two islets were assessed per case from each of three independent
samples. (e–h) Representative higher magnification images of the CAR-
SIV isoform (CAR-CT antibody; green) with (e) glucagon, (f) ZnT8, (g)
PC1/3 and (h) proinsulin in red. DAPI is shown in dark blue. No associ-
ation was observed between the CAR-SIV isoform (CAR-CT antibody;
green) and glucagon (red) (e). Scale, bars 10 μm
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co-localisation coefficient [MCC] 0.914 ± 0.016) and that this
was also true in reverse (i.e. the proportion of insulin co-
localising with CAR-SIV was high (MCC 0.912 ± 0.028;
ESM Fig. 5).
By contrast, although a large proportion of total proinsulin
co-localised with CAR-SIV (MCC 0.708 ± 0.082), this did
not hold in reverse (CAR-SIV:proinsulin, MCC 0.211 ±
0.042) because little proinsulin escaped into mature secretory
granules. Together, these findings suggest that CAR-SIV is
present in both immature and mature insulin secretory gran-
ules in human beta cells.
Cryo-immune electron microscopy confirms that CAR-SIV is
localised to insulin secretory granules To confirmmore direct-
ly that the CAR-SIV isoform localises to insulin secretory
granules, immunogold labelling was performed on thin frozen
sections using the post-embedding Tokuyasu method [24]
with antisera against CAR-SIV (10 nm gold particles) and
ZnT8 (5 nm gold particles). This revealed that both antisera
localise to secretory granules in human pancreas sections (Fig.
5); the characteristic electron-dense appearance of the granule
cores implies that they contain insulin. This was verified by
immunostaining with anti-insulin (ESM Fig. 6). By contrast,
gold particles were not concentrated in the secretory granules
of exocrine cells. Immunogold labelling of insulin secretory
granules with the CAR-CT antibody demonstrated that
localisation was least abundant in the centre of the granule
cores and preferentially displayed at their periphery (Fig.
5c,d). Labelling of ZnT8 showed a similar distribution.
Quantification of 841 CAR-SIV immunogold particles
from 21 different micrographs, across 1291 different mem-
brane intersections, revealed that CAR-SIV was most abun-
dant on mature insulin secretory granules (79%). CAR-SIV
was also observed in immature insulin granules (14.4%), but
was rarely observed in beta cell nuclei (2.5%), mitochondria
(1.0%) or endoplasmic reticulum (1.1%) or on the plasma
membrane (1.2%; Fig. 5b,e). Of note, uranyl acetate yields a
‘negative contrast’ for organelle membranes in the staining
method employed, and as a consequence the appearance of
the secretory granules differs from that seen with osmium
labelling.
To further confirm the presence of CAR-SIV in the insulin
granules at different stages of granule maturation,
immunogold labelling of normal pancreas sections to detect
proinsulin (20 nm gold particles), CAR-SIV (10 nm gold par-
ticles) and insulin (5 nm gold particles) was performed (ESM
Fig. 6). This revealed the presence of CAR-SIV in immature
granules, defined as proinsulin and CAR-SIV positive (ESM
Fig. 6c); maturing granules, defined as proinsulin, insulin and
CAR-SIV positive (ESM Fig. 6d); and mature granules, de-
fined as insulin and CAR-SIV positive (ESM Fig. 6e).
Examination of 122 granules containing CAR-SIV revealed
that six (4.9%) were also positive for proinsulin (immature
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Fig. 5 Cryoimmune electron microscopy. Immunogold labelling of
CAR-SIV (10 nm gold particles) and ZnT8 (5 nm gold particles) in thin
frozen sections of human pancreas tissue. (a) The low-magnification
image demonstrates the presence of granules in acinar cells and in islet
cells. (b, c) The higher magnification images (of the areas outlined by the
dashed black boxes in a) reveal a lack of CAR-SIV labelling of acinar cell
granules (b), but positive CAR-SIV labelling in beta cell granules (c). (d)
A higher resolution, magnified image confirms that the labelling of CAR-
SIV (10 nm gold; black arrows) and ZnT8 (5 nm gold; black arrowheads)
surrounds the beta cell granules. Scale bars, 2 μm (a), 1 μm (b, c), and
500 nm (d). (e) Relative distribution of CAR-SIV in organelles based on
quantification using line intersection counting. ER, endoplasmic
reticulum
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granules); 30 (24.6%) were also positive for proinsulin and
insulin (maturing granules), and the majority 86 (70.5%) were
positive for insulin (mature granules). Taken together, these
results suggest that CAR-SIV is present within the granule
membrane at all stages of granule maturation.
CAR-SIV co-localises with PICK1 in insulin secretory granules
PICK1 may play an important role in insulin granule traffick-
ing and maturation [18], and the SIV isoform of CAR, but not
the TVV isoform, selectively interacts with PICK1 in other
cell types [13, 15]. To assess whether CAR-SIV co-localises
with PICK1 in human beta cells, further confocal co-
immunofluorescence studies (Fig. 6) and immunoprecipita-
tion (ESM Fig. 7) studies were performed. PICK1 was readily
detected in islet endocrine cells (in both beta and non-beta
cells; Fig. 6a) and, importantly, it co-localised with CAR-
SIV in beta cells (Fig. 6a) and was co-immunoprecipitated
with CAR from EndoC-βH1 cells and human islets (ESM
Fig. 7). Pearson’s correlation analysis of the immunofluores-
cence signals (Fig. 6b) confirmed a strong association be-
tween PICK1 and both CAR-SIV (0.73 ± 0.02) and insulin
(0.84 ± 0.04).
To examine the co-localisation of PICK1, CAR-SIV and
insulin in more detail, confocal microscopy coupled with
Hyvolution software was employed to provide improved
resolution. This confirmed the intimate association between
PICK1 and the SIV isoform of CAR within insulin secretory
granules (Fig. 6c). PICK1 was also observed in association
with the secretory granules of other islet non-beta endocrine
cells, but CAR-SIV was not detected in those cells (Fig. 6).
Discussion
The present study reveals that the SIV isoform of CAR is
expressed selectively by beta cells in the human pancreas.
This finding was confirmed at both the RNA and protein
levels. We also discovered that the subcellular localisation of
CAR-SIV was atypical: the protein was found mainly within
the cytoplasmic domain of beta cells rather than at the cell
surface.
We used both immunological and molecular biological ap-
proaches to investigate CAR expression in human islet cells,
and the results were concordant. Thus, analysis of RNA ex-
tracted either from isolated human islets or laser capture mi-
crodissected islets revealed that two major isoforms of CAR,
CAR-SIVand CAR-TVV, were present. Both of these contain
a single transmembrane domain, implying that they could
each be localised within defined, membrane-limited, compart-
ments in the islet cells, as in other cell types [13]. The results
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Fig. 6 CAR-SIV co-localisation with PICK1 in the beta cell. (a)
Representative immunofluorescence staining of PICK1 (red), CAR-SIV
isoform (CAR-CT antibody; green), insulin (light blue) and DAPI (dark
blue) in non-diabetic human pancreas. Overlay of CAR-SIV and PICK1
(yellow), and CAR-SIV, PICK1 and insulin (white). (b) Pearson correla-
tion coefficient demonstrating the extent of co-localisation of CAR-SIV
with PICK1, CAR-SIV with insulin, and PICK1 with insulin. (c)
Hyvolution imaging demonstrates a close association of the CAR-SIV
isoform (CAR-CT antibody; green) and PICK1 (red) in the insulin gran-
ule (light blue) of a non-diabetic pancreas. Granules positive for insulin,
PICK1 and CAR-SIV are indicated by the orange arrows. Scale bars,
5 μm
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favoured a preponderance of the CAR-SIV isoform in islets,
and immunohistochemical analysis confirmed abundant pro-
duction of CAR-SIV protein in human islet cells, contrasting
with its absence from the exocrine pancreas. Taken as a whole,
the results suggest that the major isoform of CAR present in
human islets is CAR-SIV, although CAR-TVV is also present.
CAR-SIV is expressed preferentially in beta cells, since we
were unable to find evidence for its expression in ‘non-beta’
islet cells. By contrast, use of less selective antisera suggested
that additional isoforms of CAR (including CAR-TVV) may
be present among the other non-beta endocrine cells. This
would be consistent with the analysis of RNA expression.
The primary subcellular localisation of CAR in beta cells
has not been extensively addressed in previous work [3, 20]
but, despite this, in other cell types a consensus has emerged
that this protein is often localised within tight junctional com-
plexes at the plasma membrane [13, 14, 26]. As such, CAR
would be expected to be present at the cell surface, where it
could fulfil a secondary (presumably subverted) role as a ve-
hicle for viral entry. Thus, the present demonstration that
CAR-SIV is present in human beta cells is consistent with
the known sensitivity of these cells to infection by various
enterovirus serotypes. However, the intriguing discovery that
this isoform was localised primarily at an intracellular site in
beta cells suggests a more complex scenario (and a different
physiological role) compared with other cells in which CAR
resides mainly on the plasma membrane.
High-resolution confocal microscopic analysis was used to
examine in more detail the unexpected subcellular localisation
of CAR-SIV in beta cells. This revealed a punctate, cytoplas-
mic immunolabelling pattern for CAR-SIV, consistent with its
distribution in a distinct intracellular organelle compartment.
Additional studies demonstrated that this immunolabelling
profile correlated with that of insulin, as well as with two
additional secretory granule proteins, ZnT8 and PC1/3, there-
by implying a localisation within beta cell insulin secretory
granules. Direct confirmation of this was provided by
cryoimmune electron microscopy studies in which
immunogold methods allowed the visualisation of CAR-SIV,
principally in association with the dense-core granules char-
acteristically found in beta cells. By contrast, no labelling was
seen in the equivalent secretory granules found in adjacent
exocrine cells, implying that CAR-SIV is not absolutely re-
quired for secretory granule biogenesis in all cell types.
Importantly, and consistent with results obtained in other
cells [18], we also noted that CAR-SIV co-localised with, and
could be immunoprecipitated with, the PDZ domain protein
PICK1 in beta cells. PICK1 plays a specific role in insulin
secretory granule maturation [18, 27], and it is conceivable
that CAR-SIV serves as a selective binding partner for
PICK1 in beta cells, thereby concentrating the two proteins
within maturing secretory granules. Consistent with this hy-
pothesis, we found by immunofluorescence analysis that the
SIV isoform of CAR is much more strongly associated with
mature insulin than with proinsulin, suggesting that CAR (and
PICK1) may become concentrated in secretory granules as
these mature beyond their emergence from the trans-Golgi
network.
PICK1
ProinsulinCAR-SIV
KEY:
Insulin
Mature granuleCVB
CAR-ECD
CAR-CT
Fig. 7 CAR-SIV in beta cells. Our data demonstrate that CAR-SIV is
present at high concentrations on the insulin granule and is closely asso-
ciated with the cytoplasmic protein PICK1. CAR-SIV has previously
been shown to interact with PICK1, which is proposed to have a role in
the budding and maturation of vesicles from the trans-Golgi network.We
predict that the C-terminus of CAR-SIV faces the extragranular/cytoplas-
mic environment since its PDZ-binding domain would be available to
interact with cytoplasmic PICK1 only in this orientation. We propose that
CAR-SIV, through its interaction with PICK1, could therefore play a
hitherto unsuspected role in the maturation and trafficking of the insulin
granule. Importantly, when considering the orientation of CAR-SIV in
this model, the putative ECD of CAR-SIV, which is required for the
binding of enteroviruses, faces the interior of the secretory granule during
its maturation. This suggests that, as the insulin granule fuses with the
plasma membrane during insulin exocytosis, the ECD of CAR-SIV be-
comes displayed on the external face of the plasma membrane and is then
able to bind to enteroviruses that use this receptor, for example CVBs.
During the subsequent endocytosis of the granule, for recycling, the virus
would be transported inside the cell, where it could initiate a productive
infection
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If this model is correct, it has additional important conse-
quences. In particular, the model predicts that the C-terminus
of CAR-SIV must face the extragranular environment, since
its PDZ-binding domain is located in this region and would
only be available to interact with cytoplasmic PICK1 (or other
cytoplasmic PDZ-binding proteins) in this orientation. As
such, the putative ECD of CAR-SIV would then face the
lumen of the granule, with the single transmembrane region
serving to anchor the protein in this orientation in the limiting
membrane surrounding the granule. Thus, the region of SIV
required for the binding of enteroviruses would face the inte-
rior of the secretory granule duringmaturation. It follows from
this that the ECD of CAR-SIV would become displayed on
the external face of the plasmamembrane following the fusion
of the secretory granule and plasma membranes during
exocytosis.
These considerations are summarised in Fig. 7 and suggest
that enteroviral entry into beta cells may be facilitated under
conditions in which the rate of secretory granule exocytosis is
high (and granule membrane recycling rates are correspond-
ingly elevated). Thus, CAR-SIV appears to be configured in
beta cells such that it can interact with PDZ-binding proteins
during secretory granule maturation, and its virus-binding do-
main becomes exposed to the extracellular environment dur-
ing exocytosis. Of note, most of the autoantigens in type 1
diabetes are expressed in the insulin granule [28] and the pref-
erential localisation of viral receptors in the granule indicates a
potential mechanism bywhich CVB infection maymodify the
processing of granule proteins, to promote the generation of
autoantigens.
In support of our conclusions, Ylipaasto et al [3] dem-
onstrated that the pre-treatment of human islets with a
blocking antibody directed solely against externally ori-
ented CAR attenuated infection with Coxsackie viruses.
When coupled with our finding that the majority of CAR
is located intracellularly in islet cells, this suggests that
externalisation of the protein occurs to mediate viral entry.
Moreover, we also note Hodik et al’s [29] demonstration
that enterovirus replication complexes and viral particle
lattices are present on or near to insulin granules in
CVB acutely infected beta cells. Thus, this weight of ev-
idence is strongly supportive of our hypothesis and de-
serves further study.
In summary, we show that human beta cells express the
SIV isoform of CAR in the insulin granules. We propose that
the biochemical properties of CAR-SIV that confer the phys-
iological importance of this protein within beta cells may also
represent an ‘Achilles heel’ by which the entry and replication
of enteroviruses is facilitated.
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